From AAV to Biomarkers—Your 2025 Roadmap
Support for Your Early-Phase Gene Therapy Program
At Altasciences, we are committed to advancing gene therapies with precision and efficiency. In addition to hundreds of pre-screened AAV nonhuman primates (NHPs) available for gene therapy programs and decades of bioanalytical, nonclinical, and clinical expertise―we’ve compiled a comprehensive list of resources below:
A Comprehensive Guide to Gene Therapy and Improving AAV Efficiency
Learn more about our track record, expertise in navigating regulatory requirements, and how we ensure the safety and efficacy of AAV-based therapies (three case studies included).
In-House AAV Pre-Screening
Detailed information on our in-house AAV pre-screening methods for removing nonhuman primates from toxicology studies if they have antibodies against AAV8 serotypes. It covers two main assays: total antibody screening (TAb) and neutralizing antibody screening (NAb).
Expert Insights on Cell and Gene Therapy Development
This scientific journal reviews considerations for nonclinical cell and gene therapy development, including expert approaches to mitigate complex challenges, improve study efficiency, and maximize translational opportunities to first-in-human trials.
Altasciences’ Biomarkers by Indication
Our expertise in biomarker analysis supports critical go/no-go decision making by providing insight into a drug’s efficacy, safety, and mechanism of action. Assessed early in the drug development process, biomarker assays can validate targets and identify potential toxicity.
Ready to get your gene therapy development program started? Speak with one of our experts.
From Our Stocking to Your Inbox: Happy Holidays!
'Tis the season for a little extra joy, and we're thrilled to present "Questions From a Stocking: Holiday Edition!" in which Altascientists fully embrace the holiday spirit as they answer rapid-fire questions pulled from our new favorite stocking.
As we share these lighthearted moments, we're filled with deep gratitude for the ideas, discoveries, trials, and successes you've shared with us this year. Your partnership has been invaluable, and we're honored to support your efforts in bringing life-saving therapeutics to our global community.
From our stocking to your inbox, we wish you and your loved ones a very happy holidays.
Watch "Questions From A Stocking: Holiday Edition"
Up Close and Personal with Scott Myslinki, Director, Manufacturing
Scott Myslinski began his career in contract drug manufacturing in 2012 and joined Altasciences in 2014 as a Manufacturing Associate.
Get Started on Your Gene Therapy Preclinical Studies Today!
Our Sacramento Team is Ready to Support Your Next Gene Therapy NHP Study
With over 31,000 square feet of space and 20 animal rooms, our state-of-the-art preclinical facility in Sacramento, California, is equipped to take on your discovery and PK/PD research needs in nonhuman primates (NHPs).
With a large population of NHPs that are pre-screened for adeno-associated viruses (AAVs), we’re ready to get started on your studies immediately.
Why wait? Speak with one of our experts today to get your project started right away!
Related resources you may be interested in:
- eBook: Nonclinical Studies in Cell and Gene Therapy
- Webinar: Nonclinical AAV Gene Therapy Development
- Video: The Evolving Landscape of Gene Therapy Research